


AMENDMENTS TO THE CLAIMS

Please amend claims 1, 3-5, and 8-11 as indicated below. Deletions appear in ~~strikethrough~~ font, and additions are underlined. The listing of claims below will replace all prior versions and listings of claims in the application.

Complete listing of claims

1. (Currently amended) Compounds A compound of formula (I)



wherein

R1 is (C₁-C₇)alkyl, hydroxy(C₁-C₇)alkyl or -(CH₂)_n-CHO, wherein n is 0-6;


R2 is nitro, cyano or halogen;

R3 is hydrogen, (C₁-C₇)alkyl or halo(C₁-C₇)alkyl;

R4 is hydrogen, (C₁-C₇)alkyl, COR₁₀ or SO₂R₁₃;

X is O or NH;

A is a group selected from:



wherein R₅, R₆, R₇, R₈ and R₉ are independently selected from hydrogen, halogen, nitro, cyano, (C₁-C₇)alkyl, halo(C₁-C₇)alkyl, cyano(C₁-C₇)alkyl, amino, mono- or di(C₁-C₇)alkylamino, amino(C₁-C₇)alkyl, hydroxy(C₁-C₇)alkyl, (C₁-C₇)alkoxy(C₁-C₇)alkyl, -NHCOR₁₀, -N(COR₁₀)₂, -COR₁₁, -OR₁₂, -OSO₂R₁₃, -SO₂R₁₄, -NHSO₂R₁₃, or -SR₁₅ or and an imide ring; or R₅ and R₆, R₆ and R₇, R₇ and R₈, or R₈ and R₉ form, together with any of the ring atom(s) to which they are attached, a condensed 5 to 7 membered aliphatic or aromatic carbocyclic ring or a condensed 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatom(s) selected from N, O and S; R₁₀ and R₁₁ are independently selected from (C₁-C₇)alkyl, (C₂-C₇)alkenyl, halo(C₁-C₇)alkyl, amino(C₁-C₇)alkyl, mono- or di(C₁-C₇)alkylamino(C₁-C₇)alkyl, (C₆-C₁₀)aryl, -N(R₁₆)₂ or and -OR₁₇; R₁₂ and R₁₅ are independently selected from hydrogen, (C₁-C₇)alkyl, (C₂-C₇)alkenyl, halo(C₁-C₇)alkyl, amino(C₁-C₇)alkyl, mono- or di(C₁-C₇)alkylamino(C₁-C₇)alkyl, (C₆-C₁₀)aryl, and -COR₁₈; R₁₃ and R₁₄ are independently selected from (C₁-C₇)alkyl or (C₂-C₇)alkenyl, halo(C₁-C₇)alkyl or and (C₆-C₁₀)aryl; R₁₆ and R₁₇ are independently selected from hydrogen, (C₁-C₇)alkyl, (C₂-C₇)alkenyl, halo(C₁-C₇)alkyl, amino(C₁-C₇)alkyl or and (C₆-C₁₀)aryl; R₁₈ is (C₁-C₇)alkyl, (C₂-C₇)alkenyl, halo(C₁-C₇)alkyl or (C₆-C₁₀)aryl; R₁₉ and R₂₀ are independently selected from hydrogen, halogen, (C₁-C₇)alkyl or and (C₂-C₇)alkenyl;

and wherein each aryl or ring residue defined above may be substituted;
~~and or a pharmaceutically acceptable salts and esters salt or ester thereof.~~

2. (Original) A compound according to claim 1, wherein R₄ is hydrogen and R₃ is methyl.
3. (Currently amended) A compound according to claim 1-~~or 2~~, wherein X ~~is~~ is O.
4. (Currently amended) A compound according to ~~any of claim 1 to 3~~claim 1, wherein R₁ is methyl or hydroxymethyl and R₂ is nitro or cyano.
5. (Currently amended) A compound according to ~~any of claims 1 to 4~~claim 1, wherein R₅, R₆, R₇, R₈ and R₉ are independently selected from hydrogen, halogen, nitro, cyano, (C₁-C₇)alkyl, (C₁-C₇)alkoxy, halo(C₁-C₇)alkyl, hydroxy(C₁-C₇)alkyl ~~or and~~ -NHCOR₁₀, wherein R₁₀ is (C₁-C₇)alkyl, halo(C₁-C₇)alkyl, hydroxy or (C₁-C₇)alkoxy.
6. (Original) A compound according to claim 5, wherein at least one of R₅, R₆, R₇, R₈ and R₉ is a halogen.
7. (Original) A compound according to claim 6, wherein at least two of R₅, R₆, R₇, R₈ and R₉ are selected from a group consisting of halogen, cyano and acetamido.

8. (Currently amended) A pharmaceutical composition comprising a compound of ~~formula (I) as claimed in claim 1 and~~ together with a pharmaceutically acceptable carrier.
9. (Currently amended) A method of hormonal therapy, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of ~~formula (I) as claimed in claim 1.~~
10. (Currently amended) A method for the treatment or prevention of an androgen receptor dependent conditions condition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1 of formula (I).
11. (Currently amended) A method according to claim 9 or 10, comprising administering a therapeutically effective amount of a the compound of formula (I) orally.